Trial reportBrain and behavior2026
Efficacy of Saffron as an Adjunct to Methylphenidate in Treating ADHD in Children Aged 6-12: A Randomized Clinical Trial.
Trial report in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionAttention-deficit/hyperactivity disorder (ADHD) is a common childhood disorder often managed with stimulant medications such as methylphenidate. Around 30% of patients with ADHD do not respond to treatment or cannot tolerate its side effects, which necessitates the consideration of alternative options. This study evaluated the effectiveness of adding the saffron extract to methylphenidate on ADHD symptoms and working memory in children aged 6-12.
methodIn a randomized clinical trial, 58 children diagnosed with ADHD were randomized into two groups: a methylphenidate (0.5-1 mg/kg/day, divided into 2-3 doses)/saffron (20-30 mg/day based on weight: 20 mg for <30 kg, 30 mg for >30 kg) group and a control group receiving only methylphenidate (0.5-1 mg/kg/day, divided into 2-3 doses) for six weeks. The severity of ADHD was evaluated using subjective (Conners' Parent Rating Scale-revised) and objective (Corsi block-span task and continuous performance test) tests at the start and end (in the sixth week) of the study.
results22 participants in the methylphenidate/saffron group and 21 in the control group completed the study. The changing trend of total ADHD scores (p = 0.002, Cohen's d = 0.85), hyperactivity score (p = 0.024, d = 0.62), impulsivity score (p = 0.031, d = 0.58), and attention score (p = 0.001, d = 0.92) was significantly different between groups based on subjective parent reports. However, no significant differences were found in impulsivity, inattention, or sustained attention on the CPT, though reaction time improved significantly (p = 0.023, d = 0.45). Scores on the Corsi Block Span Task indicated no significant changes in working memory between groups. The combination treatment was well-tolerated, with no reports of severe adverse effects.
conclusionThe findings suggest that the combination of saffron with methylphenidate may enhance subjective reports of ADHD symptoms, particularly hyperactivity and impulsivity; however, objective cognitive measures showed limited changes. Given the favorable safety profile of saffron and study limitations, this supports its potential role as a complementary option, pending confirmation in placebo-controlled trials with larger samples and long-term evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.